Analysis and Commentary STEVEN GROSSMAN 11/11/22 Analysis and Commentary STEVEN GROSSMAN 11/11/22 The F in FDA: Part 2 Read More Advocacy at a Glance STEVEN GROSSMAN 11/11/22 Advocacy at a Glance STEVEN GROSSMAN 11/11/22 Election Status Update; Alliance Webinar on Drug Supply Shortages Read More Analysis and Commentary STEVEN GROSSMAN 11/4/22 Analysis and Commentary STEVEN GROSSMAN 11/4/22 The F in FDA: Both Funding and Reforms Needed to Improve Food Programs Read More Advocacy at a Glance STEVEN GROSSMAN 11/4/22 Advocacy at a Glance STEVEN GROSSMAN 11/4/22 Patience with Election Results; Congressional Committee Leadership; New Alliance Drug Shortage Webinar Read More Advocacy at a Glance STEVEN GROSSMAN 10/28/22 Advocacy at a Glance STEVEN GROSSMAN 10/28/22 Steven Solomon’s Retirement; Communications on Foodborne Illness Read More Analysis and Commentary STEVEN GROSSMAN 10/28/22 Analysis and Commentary STEVEN GROSSMAN 10/28/22 Alliance Webinar with Dr. Suzanne Schwartz on Cyber Security and Digital Health Read More Analysis and Commentary STEVEN GROSSMAN 10/14/22 Analysis and Commentary STEVEN GROSSMAN 10/14/22 All About 3D Printing: An Example of FDA’s Growing Responsibilities Read More Advocacy at a Glance STEVEN GROSSMAN 10/14/22 Advocacy at a Glance STEVEN GROSSMAN 10/14/22 Preparing for 118th Congress; FDA’s New Food Safety Strategies Read More Analysis and Commentary STEVEN GROSSMAN 10/7/22 Analysis and Commentary STEVEN GROSSMAN 10/7/22 Increased Funding To Achieve “Intentional Excellence” in FDA Food Programs Read More Advocacy at a Glance STEVEN GROSSMAN 10/7/22 Advocacy at a Glance STEVEN GROSSMAN 10/7/22 Congress in Recess; Reagan-Udall Review testimony; and Digital Health and Cyber Security Webinar Read More Analysis and Commentary STEVEN GROSSMAN 9/30/22 Analysis and Commentary STEVEN GROSSMAN 9/30/22 “FDA and One Health” Presentation with One Health Experts, including Dr. Solomon, CVM Director, and Dr. Namandjé Bumpus, the new Chief Scientist. Read More Advocacy at a Glance STEVEN GROSSMAN 9/30/22 Advocacy at a Glance STEVEN GROSSMAN 9/30/22 CR and User Fees Passed; New OTAT name; Upcoming Webinars Read More Analysis and Commentary STEVEN GROSSMAN 9/23/22 Analysis and Commentary STEVEN GROSSMAN 9/23/22 “Celebrating 10 years of Patient-Focused Drug Development” with Dr. Theresa Mullins, CDER Associate Director for Strategic Initiatives. Read More Advocacy at a Glance STEVEN GROSSMAN 9/23/22 Advocacy at a Glance STEVEN GROSSMAN 9/23/22 CR and User Fees Next Week; Alliance participating in Reagan-Udall Review; ARPA-H Director Announced Read More Analysis and Commentary STEVEN GROSSMAN 9/16/22 Analysis and Commentary STEVEN GROSSMAN 9/16/22 FDA Boosted by President Biden’s Executive Order on Biotechnology and Biomanufacturing Read More Advocacy at a Glance STEVEN GROSSMAN 9/16/22 Advocacy at a Glance STEVEN GROSSMAN 9/16/22 FY 23 CR for Sept 19; Preview for next year appropriations; Webinar with FDA One Health Read More Advocacy at a Glance STEVEN GROSSMAN 9/9/22 Advocacy at a Glance STEVEN GROSSMAN 9/9/22 CR Likely for rest of FY22; User Fee Reauthorization More Hopeful Read More Analysis and Commentary STEVEN GROSSMAN 9/9/22 Analysis and Commentary STEVEN GROSSMAN 9/9/22 The Impact of a Continuing Resolution Read More Analysis and Commentary STEVEN GROSSMAN 9/2/22 Analysis and Commentary STEVEN GROSSMAN 9/2/22 Status of User Fee Reauthorization Legislation Read More Advocacy at a Glance STEVEN GROSSMAN 9/2/22 Advocacy at a Glance STEVEN GROSSMAN 9/2/22 FY23 CR; No Change to User Fees; FDA Human Food Programs Review Panel Members Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 11/11/22 Analysis and Commentary STEVEN GROSSMAN 11/11/22 The F in FDA: Part 2 Read More
Advocacy at a Glance STEVEN GROSSMAN 11/11/22 Advocacy at a Glance STEVEN GROSSMAN 11/11/22 Election Status Update; Alliance Webinar on Drug Supply Shortages Read More
Analysis and Commentary STEVEN GROSSMAN 11/4/22 Analysis and Commentary STEVEN GROSSMAN 11/4/22 The F in FDA: Both Funding and Reforms Needed to Improve Food Programs Read More
Advocacy at a Glance STEVEN GROSSMAN 11/4/22 Advocacy at a Glance STEVEN GROSSMAN 11/4/22 Patience with Election Results; Congressional Committee Leadership; New Alliance Drug Shortage Webinar Read More
Advocacy at a Glance STEVEN GROSSMAN 10/28/22 Advocacy at a Glance STEVEN GROSSMAN 10/28/22 Steven Solomon’s Retirement; Communications on Foodborne Illness Read More
Analysis and Commentary STEVEN GROSSMAN 10/28/22 Analysis and Commentary STEVEN GROSSMAN 10/28/22 Alliance Webinar with Dr. Suzanne Schwartz on Cyber Security and Digital Health Read More
Analysis and Commentary STEVEN GROSSMAN 10/14/22 Analysis and Commentary STEVEN GROSSMAN 10/14/22 All About 3D Printing: An Example of FDA’s Growing Responsibilities Read More
Advocacy at a Glance STEVEN GROSSMAN 10/14/22 Advocacy at a Glance STEVEN GROSSMAN 10/14/22 Preparing for 118th Congress; FDA’s New Food Safety Strategies Read More
Analysis and Commentary STEVEN GROSSMAN 10/7/22 Analysis and Commentary STEVEN GROSSMAN 10/7/22 Increased Funding To Achieve “Intentional Excellence” in FDA Food Programs Read More
Advocacy at a Glance STEVEN GROSSMAN 10/7/22 Advocacy at a Glance STEVEN GROSSMAN 10/7/22 Congress in Recess; Reagan-Udall Review testimony; and Digital Health and Cyber Security Webinar Read More
Analysis and Commentary STEVEN GROSSMAN 9/30/22 Analysis and Commentary STEVEN GROSSMAN 9/30/22 “FDA and One Health” Presentation with One Health Experts, including Dr. Solomon, CVM Director, and Dr. Namandjé Bumpus, the new Chief Scientist. Read More
Advocacy at a Glance STEVEN GROSSMAN 9/30/22 Advocacy at a Glance STEVEN GROSSMAN 9/30/22 CR and User Fees Passed; New OTAT name; Upcoming Webinars Read More
Analysis and Commentary STEVEN GROSSMAN 9/23/22 Analysis and Commentary STEVEN GROSSMAN 9/23/22 “Celebrating 10 years of Patient-Focused Drug Development” with Dr. Theresa Mullins, CDER Associate Director for Strategic Initiatives. Read More
Advocacy at a Glance STEVEN GROSSMAN 9/23/22 Advocacy at a Glance STEVEN GROSSMAN 9/23/22 CR and User Fees Next Week; Alliance participating in Reagan-Udall Review; ARPA-H Director Announced Read More
Analysis and Commentary STEVEN GROSSMAN 9/16/22 Analysis and Commentary STEVEN GROSSMAN 9/16/22 FDA Boosted by President Biden’s Executive Order on Biotechnology and Biomanufacturing Read More
Advocacy at a Glance STEVEN GROSSMAN 9/16/22 Advocacy at a Glance STEVEN GROSSMAN 9/16/22 FY 23 CR for Sept 19; Preview for next year appropriations; Webinar with FDA One Health Read More
Advocacy at a Glance STEVEN GROSSMAN 9/9/22 Advocacy at a Glance STEVEN GROSSMAN 9/9/22 CR Likely for rest of FY22; User Fee Reauthorization More Hopeful Read More
Analysis and Commentary STEVEN GROSSMAN 9/9/22 Analysis and Commentary STEVEN GROSSMAN 9/9/22 The Impact of a Continuing Resolution Read More
Analysis and Commentary STEVEN GROSSMAN 9/2/22 Analysis and Commentary STEVEN GROSSMAN 9/2/22 Status of User Fee Reauthorization Legislation Read More
Advocacy at a Glance STEVEN GROSSMAN 9/2/22 Advocacy at a Glance STEVEN GROSSMAN 9/2/22 FY23 CR; No Change to User Fees; FDA Human Food Programs Review Panel Members Read More
